In two clinical trials, supplementation with N. sativa oil and N. sativa powder led to significant reduction in VCAM-1 levels in coronary artery disease (CAD) and Hashimoto’s thyroiditis patients, whereas no significant change occurred according to the other clinical trial involving subjects with the risk factor for cardiovascular disease (CVD). This evidence concerns the gene VCAM1 and coronary artery disorder.